CLDX vs IDXX: stock comparison and AI forecast
Celldex Therapeutics, Inc. (CLDX) and Idexx Laboratories Inc /De (IDXX) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
CLDX Celldex Therapeutics, Inc.
- Price
- $29.87 -10.4% · 6M
- Market Cap
- $2.35B
- P/E Ratio
- –
- Size
- mid-cap
- AI Forecast
IDXX Idexx Laboratories Inc /De
- Market Cap
- $53.26B
- P/E Ratio
- 45.6x
- Size
- large-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- IDXX is 22.7 times larger than CLDX by market capitalization ($53.26B against $2.35B).
- CLDX turns 25127.0% of its revenue into net income, against 25.4% for IDXX.
- IDXX carries 0.98 times debt per unit of equity, against 0.11 times for CLDX.
- Both companies share the SEC industry classification In Vitro & In Vivo Diagnostic Substances.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | CLDX | IDXX |
|---|---|---|
| Market Cap | $2.35B | $53.26B |
| P/E Ratio | – | 45.56x |
| P/B Ratio | 3.61x | 28.49x |
| EPS | $-5.11 | $14.84 |
| Book Value/Share | $8.27 | $23.73 |
| Revenue/Share | $-0.02 | $59.18 |
| FCF/Share | $-3.31 | $16.55 |
Profitability & Margins
| Metric | CLDX | IDXX |
|---|---|---|
| ROE | -47.6% | 63.2% |
| ROA | -42.8% | 31.9% |
| ROIC | -50.6% | 61.6% |
| Gross Margin | – | 62.7% |
| Operating Margin | 27192.1% | 32.3% |
| Net Margin | 25127.0% | 25.4% |
| EBT Margin | 24866.1% | 31.7% |
| Tax Rate | – | 20.1% |
Financial Health
| Metric | CLDX | IDXX |
|---|---|---|
| Current Ratio | 10.97x | 1.19x |
| Quick Ratio | – | 0.88x |
| D/E Ratio | 0.11x | 0.98x |
| Financial Leverage | 1.11x | 1.98x |
| Interest Coverage | -260.2x | 8.4x |
| Working Capital | $603M | $236M |
Cash Flow
| Metric | CLDX | IDXX |
|---|---|---|
| Operating Cash Flow | -$252M | $1.42B |
| Free Cash Flow | -$260M | $1.30B |
| Capital Spending | -$8M | -$115M |
| OCF Growth YoY | – | 30.4% |
| FCF Growth YoY | – | 35.3% |
| FCF/Sales | 21117.0% | 28.0% |
| CapEx/Sales | -631.4% | 2.5% |
Operational Efficiency
| Metric | CLDX | IDXX |
|---|---|---|
| Asset Turnover | 0.00x | 1.26x |
| Receivables Turnover | – | 7.6x |
| Inventory Turnover | – | 4.5x |
| Fixed Assets Turnover | -0.1x | 6.4x |
| Days Sales Outstanding | – | 48 days |
| Days Inventory | – | 82 days |
| Payables Period | – | 32 days |
| Cash Conversion Cycle | – | 98 days |
Income Statement
| Metric | CLDX | IDXX |
|---|---|---|
| Total Revenue | -$1M | $4.66B |
| Operating Income | -$334M | $1.51B |
| Net Income | -$309M | $1.18B |
| R&D Expense | $283M | $267M |
| SG&A Expense | – | $1.29B |
| Cost of Goods Sold | – | $1.74B |
Dividend & Shareholder Information
| Metric | CLDX | IDXX |
|---|---|---|
| Shares Outstanding | 79M | 79M |
| Net Income Growth | – | 15.1% |
| EPS Growth | – | 17.7% |
CLDX vs IDXX: stock comparison and AI forecast
Which is bigger, CLDX or IDXX?
IDXX is 22.7 times larger than CLDX by market capitalization ($53.26B against $2.35B).
Which one does Intratio's AI model rank higher, CLDX or IDXX?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.